Literature DB >> 11333277

Tamoxifen: five versus ten years--is the end in sight?

J S Abrams.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11333277     DOI： 10.1093/jnci/93.9.662

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  3 in total

1.  Effects of alpha-difluoromethylornithine on local recurrence and pulmonary metastasis from MDA-MB-435 breast cancer xenografts in nude mice.

Authors:  Andrea Manni; Sharlene Washington; Laura Craig; Michael Cloud; James W Griffith; Michael F Verderame; Lindsay J Texter; David Mauger; Laurence M Demers; John F Harms; Danny R Welch
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

2.  Variants in tamoxifen metabolizing genes: a case-control study of contralateral breast cancer risk in the WECARE study.

Authors:  Jennifer D Brooks; Sharon N Teraoka; Kathleen E Malone; Robert W Haile; Leslie Bernstein; Charles F Lynch; Lene Mellemkjær; David J Duggan; Anne S Reiner; Patrick Concannon; Katherine Schiermeyer; Juan Pablo Lewinger; Jonine L Bernstein; Jane C Figueiredo
Journal:  Int J Mol Epidemiol Genet       Date:  2013-03-18

3.  Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population.

Authors:  Anne S Reiner; Charles F Lynch; Julia S Sisti; Esther M John; Jennifer D Brooks; Leslie Bernstein; Julia A Knight; Li Hsu; Patrick Concannon; Lene Mellemkjær; Marc Tischkowitz; Robert W Haile; Ronglai Shen; Kathleen E Malone; Meghan Woods; Xiaolin Liang; Monica Morrow; Jonine L Bernstein
Journal:  Breast Cancer Res       Date:  2017-07-19       Impact factor: 6.466
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.